As a member of lysine acetyltransferases, the combination of GCN5 and TAK1 prompted us to detect whether GCN5 could affect the acetylation modification level of TAK1, the results showed that the level of acetylated TAK1 was not influenced by MB3 treatment (Supplementary Fig. 5E), indicating that GCN5 might affect activation of TAK1 through the other ways in pathological cardiac hypertrophy conditions. This evidence concerns the gene MAP3K7 and cardiac hypertrophy.